ViroCell Biologics appoints new CFO
ViroCell Biologics, based in London, Dublin and New York, has appointed Brian Collins as Chief Financials Officer.
Brian Collins brings a wealth of relevant experience to the Company, having spent the last four years as CFO of the Cell and Gene Therapy Catapult (CGT Catapult), a UK-based organisation supporting companies to develop, deliver and commercialise advanced therapies. As part of his role, he was responsible for Finance, HR, IT, Operational Excellence, and Risk and Data Privacy. He will join the executive team of ViroCell consisting of Nick Maishman as Chief Operating Officer, and Susan Nichols as Chief Business Officer, in addition to John W Hadden II as CEO and Farzin Farzaneh, PhD as Chief Scientific Officer, the two co-founders of the business.
Prior to CGT Catapult, Collins was CFO of Coveris Packaging and before that he hold numerous financial and operational roles of increasing seniority at companies, including MSX International, HB Fuller and Avery Dennison.
